Tarsus Secures China Approval for TP-03, Unlocking $15M Milestone Payment
TARS sits 67% above its 52-week low of $38.51.
Summary
Tarsus Pharmaceuticals announced that its partner, Grand Pharmaceutical Group Limited, secured regulatory approval in China for TP-03 (lotilaner ophthalmic solution) 0.25% for Demodex blepharitis. This significant development triggers a $15 million milestone payment to Tarsus. The approval expands the market for Tarsus' flagship product, XDEMVY, into the substantial Chinese market, where TP-03 is now the first and only approved therapy for the condition. This strategic expansion is expected to generate additional revenue through future sales milestones and tiered royalties, building on the company's strong 2025 financial results and pipeline advancements. Traders should monitor Grand Pharma's commercial launch and initial sales performance in the Greater China region.
At the time of this announcement, TARS was trading at $64.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $38.51 to $85.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.